Mr. Zakrzewski has over 30 years of experience as an executive in the biotechnology and pharmaceutical industry. He currently serves on the Board of Directors of a number of publicly & privately held companies. He is the founder of a number of biotechnology companies, and is involved in a number of philanthropic activities.  During his operating career he was Chairman and CEO of Amarin Pharmaceuticals, a publicly traded company focused on the development and commercialization of cardiovascular drugs based on Omega 3‘s from 2010 to 2013, successfully developing and launching Vascepa®. Mr. Zakrzewski served as a Venture Partner with Orbimed, in 2010 and 2011. Prior to this, he was Chairman, President & Chief Executive Officer of Xcellerex, a privately held company focusing on commercializing its proprietary next generation biologics manufacturing technology for biotherapeutics and vaccines from 2007 to 2010. Xcellerex was sold to GE Healthcare.  Mr. Zakrzewski also served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular drugs from 2005 to 2007, overseeing the launch of Lovaza®. Reliant Pharmaceuticals was sold to GSK plc. Prior to this, Mr. Zakrzewski served in a variety of executive level positions at Eli Lilly & Company for 17 years including R&D, manufacturing, finance and business development. His most recent position had global responsibility for all business and corporate development.  Mr. Zakrzewski is an inventor on numerous patents and has been involved in or led financings amounting to several billion dollars for both private and public companies. Over his career, he has served as a member of the board of directors of over 25 companies, with a number of successful exits for shareholders. He received a BS in Chemical Engineering from Drexel University in 1986, an MS in Biochemical Engineering from Drexel University in 1988, and an MBA in Finance in 1992 from Indiana University.